Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera.

Meyer, Sara C.; Steinmann, Eva; Lehmann, Thomas; Muesser, Patricia; Passweg, Jakob R; Skoda, Radek C; Tsakiris, Dimitrios A (2017). Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera. BioMed research international, 2017, p. 9876819. Hindawi 10.1155/2017/9876819

[img]
Preview
Text
9876819.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (1MB) | Preview

BACKGROUND

Myeloproliferative neoplasms (MPN) encounter thromboses due to multiple known risk factors. Heparin-induced thrombocytopenia (HIT) is a thrombotic syndrome mediated by anti-platelet factor 4 (PF4)/heparin antibodies with undetermined significance for thrombosis in MPN. We hypothesized that anti-PF4/heparin Ab might occur in MPN and promote thrombosis.

METHODS

Anti-PF4/heparin antibodies were analyzed in 127 MPN patients including 76 PV and 51 ET. Screening, validation testing, and isotype testing of anti-PF4/heparin Ab were correlated with disease characteristics.

RESULTS

Anti-PF4/heparin antibodies were detected in 21% of PV and 12% of ET versus 0.3-3% in heparin-exposed patients. Validation testing confirmed anti-PF4/heparin immunoglobulins in 15% of PV and 10% of ET. Isotype testing detected 9.2% IgG and 5.3% IgM in PV and exclusively IgM in ET. IgG-positive PV patients encountered thromboses in 57.1% suggesting anti-PF4/heparin IgG may contribute to higher risk for thrombosis in MPN. Overall, 45% of PV patients experienced thromboses with 11.8% positive for anti-PF4/heparin IgG versus 7.1% in PV without thrombosis.

CONCLUSION

Anti-PF4/heparin antibodies occur endogenously and more frequently in MPN than upon heparin exposure. Thrombotic risk increases in anti-PF4/heparin IgG-positive PV reflecting potential implications and calling for larger, confirmatory cohorts. Anti-PF4/heparin IgG should be assessed upon thrombosis in PV to facilitate avoidance of heparin in anti-PF4/heparin IgG-positive PV.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory

UniBE Contributor:

Meyer, Sara Christina

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2314-6141

Publisher:

Hindawi

Language:

English

Submitter:

Julia Elisa Garcia

Date Deposited:

22 Dec 2023 06:26

Last Modified:

14 Jan 2024 02:42

Publisher DOI:

10.1155/2017/9876819

PubMed ID:

28698883

BORIS DOI:

10.48350/190301

URI:

https://boris.unibe.ch/id/eprint/190301

Actions (login required)

Edit item Edit item
Provide Feedback